Literature DB >> 31618687

Nanomedicinal strategies as efficient therapeutic interventions for delivery of cancer vaccines.

Sarwar Beg1, S M Kawish2, Sunil K Panda3, Mohammed Tarique4, Arshi Malik5, Sarah Afaq5, Awad Saeed Al-Samghan6, Jawed Iqbal7, Kainat Alam8, Mahfoozur Rahman9.   

Abstract

The applications of gene therapy-based treatment of cancers were started almost two decades back as a boon over the chemotherapeutic treatment strategies. Gene therapy helps in correcting the genetic sequences for treatment of cancers, thus also acts like a vaccine to induce the cellular and humoral immunity. However, the cancer vaccines typically suffer from a series of biopharmaceutical challenges due to poor solubility, low systemic availability and lack of targeting ability. Owing to these challenges, the physicians and pharmaceutical scientists have explored the applications of nanocarriers as quite promising systems for effective treatment against the tumors. A series of nanotherapeutic systems are available to date for diverse drug therapy applications. Systematic understanding on the preparation, evaluation and application of nanomedicines as a carrier system for delivering the cancer vaccines is highly important. The present review article provides an in-depth understanding on the challenges associated with cancer vaccine delivery and current opportunities with diverse nanomedicinal carriers being available for treatment of cancers.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Drug targeting; Immune response; Nanomedicines; Nanoparticles; Vaccines

Mesh:

Substances:

Year:  2019        PMID: 31618687     DOI: 10.1016/j.semcancer.2019.10.005

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  3 in total

1.  Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits.

Authors:  Michael-Joseph Gorbet; Akansha Singh; Chenkai Mao; Steven Fiering; Ashish Ranjan
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

2.  Inhibitory effects of brusatol delivered using glycosaminoglycan‑placental chondroitin sulfate A‑modified nanoparticles on the proliferation, migration and invasion of cancer cells.

Authors:  Xin Chen; Tailang Yin; Baozhen Zhang; Beini Sun; Jie Chen; Tianxia Xiao; Baobei Wang; Mengxia Li; Jing Yang; Xiujun Fan
Journal:  Int J Mol Med       Date:  2020-06-03       Impact factor: 4.101

3.  CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.

Authors:  Xiaopei Hao; Yao Zhang; Xiaoli Shi; Hanyuan Liu; Zhiying Zheng; Guoyong Han; Dawei Rong; Chuanyong Zhang; Weiwei Tang; Xuehao Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-09-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.